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Abstract 
Pyrazinamide is one of the four first line drugs for 
treatment of tuberculosis. It has been widely accepted, 
that pyrazinamide (PZA) resistance in Mycobacterium 
tuberculosis is correlated with mutations in the pncA gene. 
In the present study, pyrazinamide susceptibility was 
tested in 65 clinical isolates of Mycobacterium tuberculosis 
by pncA gene sequencing and was then correlated with 
pyrazinamidase activity. 68% of the resistant isolates 
showed mutation in the pncA gene which was further 
correlated with an assay for pyrazinamidase activity. 
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Introduction 
Tuberculosis (TB) still remains one of the leading causes of 
morbidity and mortality in the world. At present one-third of the 
world’s population is infected with Mycobacterium tuberculosis, the 
causative agent of TB. In 2011, 1 million HIV negative people died 
from the disease and 8.7 million new cases were estimated of which 
13% are coinfected with HIV [1]. Pyrazinamide (PZA) is one of the 
most important drugs in both first and second-line treatment of TB. 
It is particularly effective against latent TB infection and allows 
anti-tuberculous treatment to be shortened from 9 to 6 months [2].  
PZA is one of the few anti-TB drugs effective against persistent 
tubercle bacilli. It is only active against M. tuberculosis and M. 
africanum in the host, while M. bovis is inherently resistant to it. 
Since the global resurgence of drug resistant TB strains, an 
increasing number of PZA resistant strains have been observed. 
PZA is a prodrug which is converted into the active substance 
pyrazinoic acid (POA) by M. tuberculosis at low pH medium [3]. In 
M. tuberculosis PZA is converted to POA by pncA gene [4]. PZA 
susceptible M. tuberculosis possesses a functional pyrazinamidase 
and mutations in this gene have been reported leading to reduction 
or complete loss of pyrazinamidase activity, which in turn make 
the bacteria resistant to PZA [5,6]. Recent study has shown that 
mutations in the rpsA gene are associated with PZA resistance in 
clinical isolates without mutations in pncA [7]. 
PZA is active only in an acidic microenvironment (pH 5.5) and 
such low pH in itself inhibits the growth of the bacilli. Hence 
growth-based testing for PZA resistance is both difficult and 
unreliable. It has also been reported that even modest variations in 
inoculum size can alter the pH and lead to differing results [8]. The 
aim of the present study was to identify the mutations in the pncA 
gene associated with PZA resistance in the clinical isolates of M. 
tuberculosis from Kerala and also correlate the results with 
pyrazinamidase activity assay.  
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Materials and Methods 
Bacterial Isolates 
The collection of samples, biochemical testing and drug sensitivity 
profiling of the samples was done as reported earlier [9]. For this 
study well grown clinical isolates of M. tuberculosis were selected in 
random as no information was available on the prevalence of PZA 
resistance in our state or in South India when this study was first 
initiated. Pyrazinamide-LJ slants (HiMedia) were purchased and 
M. tuberculosis isolates collected from the standard LJ media were 
inoculated into two of them (pH 5.5) with one slant containing 
pyrazinamide (100mg/ml) and one without the drug (control). 
Pyrazinamidase Activity Assay 
Pyrazinamidase (PZase) activity was determined by Wayne's 
method [10]. Briefly, a heavy loopful of M. tuberculosis colonies was 
obtained from cultures that were actively growing in LJ medium 
and inoculated onto the surfaces of two agar butt tubes, each 
containing 5 ml of Wayne's medium supplemented with 100 μg/ml 
of PZA (Sigma-Aldrich, USA). The tubes were incubated at 37°C. 
Four days after incubation, 1 ml of freshly prepared 1% Ferrous 
Ammonium Sulphate was added to the first tube. The tube was left 
at room temperature for 30 minutes and examined. The assay was 
positive if a pink band was present on the subsurface of the agar. If 
the test was negative, the test was repeated with a second tube and 
examined after 7 days of incubation. The results were blindly read 
by two independent observers. M. bovis BCG and M. tuberculosis 
H37Rv were used as negative and positive controls, respectively. 
DNA Sequencing and Analysis   
DNA of all the isolates was subjected to an in house developed 
tetraplex PCR to confirm whether they are M. tuberculosis or NTM 
[11]. pncA gene was amplified  and sequenced using primers 
pncA1F - 5’TCGGTCATGTTCGCGATCG 3’ and pncA4 
5’CGCTTGCGGCGAGCGCTCCA 3’ – (Figure 1). The sequences 
were subjected to BLAST analysis in the M. tuberculosis DNA 
sequence database (http://genolist.pasteur.fr/TubercuList/) for 
mutation analysis. 
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Results and Discussion 
Correlation of drug resistance with a defect in a specific drug 
resistant gene has been observed for several anti-TB drugs. Drug 
resistance phenotype and mutations in the drug resistance genes 
has been observed in varying proportions for drugs such as 
ofloxacin (gyrA 75–94%), Rifampicin, (rpoB 90–95%), Ethambutol 
(embB 47–65%) and isoniazid (katG 31–97% /inhA 8–43%) [3,12]. 
The correlation of PZA resistance and mutation in pncA has also 
been reported in a variety of ranges from as low as 41% in Taiwan 
[13] to as high as 97% in Japan [14] and S. Korea [15]. In the present 
study 65 M. tuberculosis strains with known microbiological PZA 
susceptibility or resistance were analyzed. They were subjected to 
pncA gene sequence analysis and out of 31 PZA resistant clinical 
isolates 68% (21 isolates) showed mutations in the pncA gene. 
 
 
Fig 1: Amplification of pncA target for identification of mutations 
Lane 1: 100bp Ladder (NEB); Lane 2: pncA amplified from an M. 
tuberculosis clinical isolate 
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The uniqueness in the mutations of pncA gene is its diversity and 
scattering along the whole gene though there does appear to be 
some degree of clustering at three regions of pncA protein (3 to 17, 
61 to 85, and 132 to 142). These regions are likely to contain 
catalytic sites for the PZase enzyme [16]. Ten isolates 15.4% showed 
mutations which include codons 49, 65, 68, 76, 132, 139, 180. Five 
clinical isolates (RGTB 143, 342, 343, 431 and 502) had a mutation in 
codon 65 (TCC→TCT; Ser→Ser) that has been reported by other 
groups too [17, 18, 19, 20]. RGTB 399 had a mutation in codon 49; 
GAC→GAG, Asp→Glu; RGTB 416 had a mutation in codon 68; 
TGG→GGG, Trp→Gly. RGTB 495 had a mutation in codon 132 - 
GGT→GCT, Gly→Ala. We report that the mutations observed in 
codons 49, 68 and 132 are novel mutations that have been observed 
in the present study. RGTB 233 had a mutation in codon 76 - 
ACT→CCT, Thr→Pro that has been reported by other groups [19, 
21, 22, 23]. RGTB 86 had a mutation in codon 180 - GTC→TTC, 
Val→Phe that has been reported by other groups [17, 19, 23]. RGTB 
143 had mutations both at codon 65 and codon 139 - GTG→GCG, 
Val→Ala. Mutation at codon 139 has already been reported to be 
responsible for pyrazinamide resistance [19, 22, 24]. Thus, although 
this sample also has a silent mutation at codon 65, mutation at 
codon 139 can confer resistance to the drug. In a previous study, it 
has been reported that Cys-138, Ala-134, Thr-135, Trp-68, and Asp-
8 in the M. tuberculosis PZase could be key residues for hydrolysis 
of PZA [25]. Hence the mutations occurring within or close to the 
regions containing these residues could result in conformational 
modifications of the active site of the PZase and consequently, in a 
loss of PZase activity. In this study the mutations found are in and 
near the suggested positions. So these can lead to the loss of PZase 
activity and thereby conferring resistance to the drug.  
Strains of M. tuberculosis that are resistant to PZA are often 
defective in PZase activity. Isolates that showed mutations in the 
pncA gene were subjected to pyrazinamidase assay to correlate the 
mutation results with loss of PZase activity. Pyrazinamidase test is 
rapid, economical and easy to perform. PZA susceptible M. 
tuberculosis H37Rv developed a pink band on the surface after the 
addition of ferrous ammonium sulfate. This showed that PZase is 
active. But PZA resistant M. bovis BCG and mutated clinical isolates 
did not show any color development. This showed a loss of PZase 
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activity in them. The five clinical isolates which had silent mutation 
developed a pink colour showing that they were really susceptible 
and had PZase activity. Other samples failed to develop colour as 
they had lost their PZase activity. This showed that they were 
resistant to the drug. 
In conclusion, PCR based sequencing is an effective method to 
identify PZA resistance and can be correlated with PZase assay 
because the enzymatic activity is very sensitive to sequence 
alterations in any region of the protein. 
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